title: Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits?
authors.forename: B
authors.initials: B
authors.lastname: Siegmund
authors.forename: H
authors.initials: H
authors.lastname: Richter
authors.forename: H
authors.initials: H
authors.lastname: Pollmann
mesh_terms: D001779:Blood Coagulation Factors / Q000008:administration & dosage*; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D005167:Factor VII / Q000008:administration & dosage; D005169:Factor VIII / Q000037:antagonists & inhibitors; D015942:Factor VIIa; D017048:Health Care Costs; D006467:Hemophilia A / Q000188:drug therapy*; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; D005167:Factor VII; D005169:Factor VIII; C103587:recombinant FVIIa; C065655:anti-inhibitor coagulant complex; D015942:Factor VIIa